# OnCo record entrectinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/entrectinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "entrectinib" ;
  schema:name "Entrectinib"@en ;
  schema:description "Entrectinib (Rozlytrek) is a pill for NTRK-fusion cancers and ROS1 lung cancer that reaches brain metastases."@en ;
  schema:url <https://onco.cc/drugs/entrectinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Entrectinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q25323953> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=entrectinib>, <https://www.nice.org.uk/guidance/ta1118>, <https://www.nice.org.uk/guidance/ta644>, <https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek>, <https://www.nice.org.uk/guidance/ta643> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)" ;
  schema:alternateName "Rozlytrek" ;
  onco:approval "JP 2019: NTRK fusion solid tumours", "US 2019: ROS1-positive metastatic NSCLC; NTRK fusion solid tumours (≥12 years, extended to ≥1 month 2023)", "EU 2020: Same", "UK 2020: NTRK fusion-positive solid tumours: NICE TA644 (12 August 2020) recommended entrectinib within the Cancer Drugs Fund; it was replaced by TA1118 (terminated appraisal, 7 January 2026) because the company did not make a submission, and only people already on treatment continue", "England (NICE) 2020: NTRK fusion-positive solid tumours, including colorectal cancer", "England (NICE) 2020: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor" ;
  onco:acceleratedApproval "US 2019-08-15: Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy . *", "US 2023-10-20: Formulation: Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation as detected by an FDA-approved test, are metastatic or where surgical resection is likely to result in severe morbidity and have progressed following treatment or have no satisfactory alternative therapy ." ;
  onco:related <https://onco.cc/biomarkers/ros1-fusion/>, <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/salivary-gland/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/ros1-positive-nsclc/>, <https://onco.cc/cancers/ntrk-fusion-nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/alk/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/blood-brain-barrier/> ;
  onco:trials <https://onco.cc/trials/nct05170204/>, <https://onco.cc/trials/nct02568267/>, <https://onco.cc/trials/nct04302025/>, <https://onco.cc/trials/nct04603807/>, <https://onco.cc/trials/nct02650401/>, <https://onco.cc/trials/profile-1001-ros1/> .